Katherine O'Neill1, Michael M Tunney2, Elinor Johnston3, Stephen Rowan4, Damian G Downey5, Jacqueline Rendall5, Alastair Reid5, Ian Bradbury6, J Stuart Elborn3, Judy M Bradley7. 1. Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Northern Ireland. Electronic address: k.oneill@qub.ac.uk. 2. School of Pharmacy, Queen's University Belfast, Northern Ireland. 3. Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Northern Ireland. 4. South Eastern Health and Social Care Trust, Belfast, Northern Ireland. 5. Belfast Health and Social Care Trust, Belfast, Northern Ireland. 6. Frontier Science (Scotland) Ltd, Kincaid, Scotland. 7. Clinical Research Facility, Queen's University Belfast, Northern Ireland.
Abstract
BACKGROUND: Lung clearance index (LCI) has good clinimetric properties and an acceptable feasibility profile as a surrogate end point in cystic fibrosis (CF). Although most studies to date have been in children, increasing numbers of adults with CF also have normal spirometric findings. Further study of LCI as an end point in adults with CF is required. Therefore, the purpose of this study was to determine the clinimetric properties of LCI across the age range of people with CF. METHODS: Clinically stable adults and children with CF and age-matched healthy control subjects were recruited. RESULTS: LCI and spirometry data for 110 subjects with CF and 61 control subjects were collected at a stable visit. The CF Questionnaire-Revised (CFQ-R) was completed by 80 of 110 subjects with CF. Fifty-six subjects with CF completed a second stable visit. The LCI coefficient of variation percent was 4.1% in adults and 6.3% in children with CF. The coefficient of repeatability of LCI was 1.2 in adults and 1.3 in children. In both adults and children, LCI (area under the receiving operator characteristic curve [AUCROC] = 0.93 and 0.84, respectively) had greater combined sensitivity and specificity to discriminate between people with CF and control subjects when compared with FEV1 (AUCROC = 0.88 and 0.60, respectively) and forced expiratory flow at 25% to 75% of the curve (AUCROC = 0.87 and 0.68, respectively). LCI correlated significantly with the CFQ-R treatment burden in adults (r = -0.37; P < .01) and children (r = -0.50; P < .01). Washout tests were successful in 90% of subjects with CF and were perceived as comfortable and easy to perform in both adults and children. CONCLUSIONS: These data support the use of LCI as a surrogate outcome measure in CF clinical trials in adults as well as in children. Copyright Â
BACKGROUND: Lung clearance index (LCI) has good clinimetric properties and an acceptable feasibility profile as a surrogate end point in cystic fibrosis (CF). Although most studies to date have been in children, increasing numbers of adults with CF also have normal spirometric findings. Further study of LCI as an end point in adults with CF is required. Therefore, the purpose of this study was to determine the clinimetric properties of LCI across the age range of people with CF. METHODS: Clinically stable adults and children with CF and age-matched healthy control subjects were recruited. RESULTS:LCI and spirometry data for 110 subjects with CF and 61 control subjects were collected at a stable visit. The CF Questionnaire-Revised (CFQ-R) was completed by 80 of 110 subjects with CF. Fifty-six subjects with CF completed a second stable visit. The LCI coefficient of variation percent was 4.1% in adults and 6.3% in children with CF. The coefficient of repeatability of LCI was 1.2 in adults and 1.3 in children. In both adults and children, LCI (area under the receiving operator characteristic curve [AUCROC] = 0.93 and 0.84, respectively) had greater combined sensitivity and specificity to discriminate between people with CF and control subjects when compared with FEV1 (AUCROC = 0.88 and 0.60, respectively) and forced expiratory flow at 25% to 75% of the curve (AUCROC = 0.87 and 0.68, respectively). LCI correlated significantly with the CFQ-R treatment burden in adults (r = -0.37; P < .01) and children (r = -0.50; P < .01). Washout tests were successful in 90% of subjects with CF and were perceived as comfortable and easy to perform in both adults and children. CONCLUSIONS: These data support the use of LCI as a surrogate outcome measure in CF clinical trials in adults as well as in children. Copyright Â
Authors: Lauren M Zell-Baran; Silpa D Krefft; Camille M Moore; Jenna Wolff; Richard Meehan; Cecile S Rose Journal: Respir Med Date: 2020-12-05 Impact factor: 3.415
Authors: Laura J Sherrard; Gisli G Einarsson; Elinor Johnston; Katherine O'Neill; Leanne McIlreavey; Stephanie J McGrath; Deirdre F Gilpin; Damian G Downey; Alastair Reid; Noel G McElvaney; Richard C Boucher; Marianne S Muhlebach; J Stuart Elborn; Michael M Tunney Journal: J Cyst Fibros Date: 2019-03-21 Impact factor: 5.482
Authors: Sanja Stanojevic; Stephanie D Davis; George Retsch-Bogart; Hailey Webster; Miriam Davis; Robin C Johnson; Renee Jensen; Maria Ester Pizarro; Mica Kane; Charles C Clem; Leah Schornick; Padmaja Subbarao; Felix A Ratjen Journal: Am J Respir Crit Care Med Date: 2017-05-01 Impact factor: 21.405
Authors: Katherine O'Neill; Fidelma Moran; Michael M Tunney; J Stuart Elborn; Ian Bradbury; Damian G Downey; Jackie Rendall; Judy M Bradley Journal: BMJ Open Respir Res Date: 2017-01-12
Authors: Freda Werdiger; Martin Donnelley; Stephen Dubsky; Rhiannon P Murrie; Richard P Carnibella; Chaminda R Samarage; Ying Y How; Graeme R Zosky; Andreas Fouras; David W Parsons; Kaye S Morgan Journal: Sci Rep Date: 2020-07-02 Impact factor: 4.379